Asset

LUNACALCIPOL

OPKO Health Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00742716phase2completed2008-10-012010-02-01OPKO IP Holdings II, Inc.Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
NCT00384098phase2completed2006-09-012007-05-01OPKO Health, Inc.Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)